Literature DB >> 10656461

Histology and sensitivity to anticancer drugs of two human non-small cell lung carcinomas implanted in the pleural cavity of nude mice.

L Kraus-Berthier1, M Jan, N Guilbaud, M Naze, A Pierré, G Atassi.   

Abstract

We have established two metastatic models of human non-small cell lung carcinoma (NSCLC)-the NCI-H460 large-cell carcinoma and the A549 adenocarcinoma-by inoculating tumor cells into the pleural space of nude mice. The objectives of this work were as follows: (a) to study the histological characteristics and growth and dissemination patterns of these tumors in nude mice; (b) to assess their sensitivity to drugs that have demonstrated significant clinical therapeutic effect in the treatment of NSCLC; and (c) to investigate the antitumor activity of S 16020-2, a new olivacine derivative, currently in Phase II clinical evaluation. In each of the two models, all animals developed lung tumors, resulting in 100% mortality. Histopathological study showed that these two tumors spread locally to contiguous structures, including the mediastinal pleura and diaphragm, with histological characteristics consistent with the human pathology. Anticancer drugs used for the treatment of NSCLC, such as cisplatin, doxorubicin, vinblastine, and etoposide, enhanced the life span of treated mice in the two models and were more active in the NCI-H460 than in the A549 model. The increases of survival time as compared to control groups were from 60 (P < or = 0.05) to 83% (P < or = 0.01) and from 21 to 40% for NCI-H460 and A549, respectively. Vinorelbine, paclitaxel, and irinotecan showed similar activities in the two models and increased the survival of treated mice by between 38 and 79% (P < or = 0.001) and between 58 (P < or = 0.01) and 78% in the NCI-H460 and A549 models, respectively. However, none of these drugs was curative, reflecting the resistance of this disease to chemotherapy. S 16020-2 exhibited a remarkable antitumor activity, increasing the survival by 82% (P < or = 0.01) for NCI-H460 and by 126% (P < or = 0.001) for A549. This drug was among the most active compounds in these models, thereby indicating its potential for the chemotherapy of this disease.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10656461

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  12 in total

1.  Pre-clinical imaging for establishment and comparison of orthotopic non-small cell lung carcinoma: in search for models reflecting clinical scenarios.

Authors:  Rozina Aktar; Antje Dietrich; Falk Tillner; Shady Kotb; Steffen Löck; Henning Willers; Michael Baumann; Mechthild Krause; Rebecca Bütof
Journal:  Br J Radiol       Date:  2018-10-11       Impact factor: 3.039

2.  Anti-invasive effects of CXCR4 and FAK inhibitors in non-small cell lung carcinomas with mutually inactivated p53 and PTEN tumor suppressors.

Authors:  Miodrag Dragoj; Jasna Bankovic; Evangelia Sereti; Sofija Jovanovic Stojanov; Konstantinos Dimas; Milica Pesic; Tijana Stankovic
Journal:  Invest New Drugs       Date:  2017-07-22       Impact factor: 3.850

3.  TH-302, a hypoxia-activated prodrug with broad in vivo preclinical combination therapy efficacy: optimization of dosing regimens and schedules.

Authors:  Qian Liu; Jessica D Sun; Jingli Wang; Dharmendra Ahluwalia; Amanda F Baker; Lee D Cranmer; Damien Ferraro; Yan Wang; Jian-Xin Duan; W Steve Ammons; John G Curd; Mark D Matteucci; Charles P Hart
Journal:  Cancer Chemother Pharmacol       Date:  2012-03-02       Impact factor: 3.333

4.  Urokinase plasminogen activator receptor induced non-small cell lung cancer invasion and metastasis requires NHE1 transporter expression and transport activity.

Authors:  J J Provost; D Rastedt; J Canine; T Ngyuen; A Haak; C Kutz; N Berthelsen; A Slusser; K Anderson; G Dorsam; M A Wallert
Journal:  Cell Oncol (Dordr)       Date:  2012-01-31       Impact factor: 6.730

5.  Bioluminescent orthotopic mouse models of human localized non-small cell lung cancer: feasibility and identification of circulating tumour cells.

Authors:  Pierre Mordant; Yohann Loriot; Benoit Lahon; Yves Castier; Guy Lesèche; Jean-Charles Soria; Marie-Catherine Vozenin; Charles Decraene; Eric Deutsch
Journal:  PLoS One       Date:  2011-10-11       Impact factor: 3.240

6.  A Novel Strategy to Improve the Therapeutic Efficacy of Gemcitabine for Non-Small Cell Lung Cancer by the Tumor-Penetrating Peptide iRGD.

Authors:  Qing Zhang; Yang Zhang; Ke Li; Haiyu Wang; Huizhong Li; Junnian Zheng
Journal:  PLoS One       Date:  2015-06-12       Impact factor: 3.240

7.  Detection of tumor cell-specific mRNA and protein in exosome-like microvesicles from blood and saliva.

Authors:  Jieping Yang; Fang Wei; Christopher Schafer; David T W Wong
Journal:  PLoS One       Date:  2014-11-14       Impact factor: 3.240

8.  CXCR1/2 antagonism with CXCL8/Interleukin-8 analogue CXCL8(3-72)K11R/G31P restricts lung cancer growth by inhibiting tumor cell proliferation and suppressing angiogenesis.

Authors:  Muhammad Noman Khan; Bing Wang; Jing Wei; Yingqiu Zhang; Qiang Li; Xuelin Luan; Jya-Wei Cheng; John R Gordon; Fang Li; Han Liu
Journal:  Oncotarget       Date:  2015-08-28

9.  Nilotinib potentiates anticancer drug sensitivity in murine ABCB1-, ABCG2-, and ABCC10-multidrug resistance xenograft models.

Authors:  Amit K Tiwari; Kamlesh Sodani; Chun-Ling Dai; Alaa H Abuznait; Satyakam Singh; Zhi-Jie Xiao; Atish Patel; Tanaji T Talele; Liwu Fu; Amal Kaddoumi; James M Gallo; Zhe-Sheng Chen
Journal:  Cancer Lett       Date:  2012-10-09       Impact factor: 8.679

10.  PEG-pHPMAm-based polymeric micelles loaded with doxorubicin-prodrugs in combination antitumor therapy with oncolytic vaccinia viruses.

Authors:  Eduardo Ruiz-Hernández; Michael Hess; Gustavo J Melen; Benjamin Theek; Marina Talelli; Yang Shi; Burcin Ozbakir; Erik A Teunissen; Manuel Ramírez; Diana Moeckel; Fabian Kiessling; Gert Storm; Hans W Scheeren; Wim E Hennink; Aladar A Szalay; Jochen Stritzker; Twan Lammers
Journal:  Polym Chem       Date:  2014-03-07       Impact factor: 5.582

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.